Recently published data support long-term triglyceride (TG) and pancreatitis reduction with volanesorsen in patients with familial chylomicronaemia syndrome (FCS).
In an open-label extension study of 62 patients who had previously received volanesorsen or placebo in the Phase 3 APPROACH or COMPASS studies, or were treatment-naïve, 46 completed 52 weeks and 21 completed 104 weeks treatment.
Pemafibrate more effective than bezafibrate in hypertriglyceridaemia
The selective PPAR-α agonist, pemafibrate, is more effective at lowering serum triglyceride than the non-selective PPAR-α agonist, bezafibrate, according to results of a randomised crossover study in 60 patients with hypertriglyceridaemia (fasting triglyceride [TG] ≥150 mg/dL) treated by cardiologists in Japan.
Phase 2 data show promising effects of evinacumab in hypertriglyceridaemia
A Phase 2 trial of evinacumab in patients with severe hypertriglyceridaemia and a history of hospitalisation for acute pancreatitis has not met its primary endpoint, but safety data and changes in lipid and lipoprotein levels support further evaluation in larger trials, conclude the study authors in Nature Medicine.
Pegozafermin reduces liver fat and improves liver function and TG
The glycoPEGylated FGF21 analogue, pegozafermin, is generally well tolerated and associated with clinically meaningful reductions in liver fat, measures of liver function, and circulating lipids. These are the recent findings of a Phase 1b/2a double-blind, placebo-controlled, multiple-ascending-dose study of pegozafermin (3, 9, 18, or 27 mg once weekly; 18 or 36 mg once every 2 […]
Genetic testing for pancreatitis risk
Genetic testing may help identify patients with hypertriglyceridemia who are at greatest risk of developing pancreatitis and may benefit from novel triglyceride-lowering therapies, US researchers have concluded.
PROMINENT trial misses primary endpoint
Newly published results of the PROMINENT trial have shown that the SPPARα modulator, pemafibrate, affects a range of plasma lipid levels in patients with type 2 diabetes and mild-to-moderate hypertriglyceridemia (fasting median 271 mg/dL), but does not reduce cardiac events.
